153 related articles for article (PubMed ID: 27749455)
1. A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy.
Minar P; Jackson K; Tsai YT; Rosen MJ; Northcutt M; Khodoun M; Finkelman FD; Denson LA
Inflamm Bowel Dis; 2016 Nov; 22(11):2641-2647. PubMed ID: 27749455
[TBL] [Abstract][Full Text] [Related]
2. Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.
Minar P; Jackson K; Tsai YT; Sucharew H; Rosen MJ; Denson LA
Inflamm Bowel Dis; 2017 Dec; 24(1):198-208. PubMed ID: 29272485
[TBL] [Abstract][Full Text] [Related]
3. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
Colman RJ; Tsai YT; Jackson K; Boyle BM; Noe JD; Hyams JS; D'Haens GRAM; van Limbergen J; Rosen MJ; Denson LA; Minar P
Inflamm Bowel Dis; 2021 Jun; 27(7):1045-1051. PubMed ID: 32944769
[TBL] [Abstract][Full Text] [Related]
4. Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease.
Minar P; Haberman Y; Jurickova I; Wen T; Rothenberg ME; Kim MO; Saeed SA; Baldassano RN; Stephens M; Markowitz J; Rosh J; Crandall WV; Heyman MB; Mack DR; Griffiths AM; Baker SS; Hyams JS; Kugathasan S; Denson LA
Inflamm Bowel Dis; 2014 Jun; 20(6):1037-48. PubMed ID: 24788216
[TBL] [Abstract][Full Text] [Related]
5. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease.
Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
Inflamm Bowel Dis; 2018 Sep; 24(10):2266-2271. PubMed ID: 29718327
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
[TBL] [Abstract][Full Text] [Related]
7. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease.
Xiong Y; Mizuno T; Colman R; Hyams J; Noe JD; Boyle B; Tsai YT; Dong M; Jackson K; Punt N; Rosen MJ; Denson LA; Vinks AA; Minar P
Clin Pharmacol Ther; 2021 Jun; 109(6):1639-1647. PubMed ID: 33354765
[TBL] [Abstract][Full Text] [Related]
8. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
9. Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.
Frymoyer A; Piester TL; Park KT
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):723-7. PubMed ID: 26890885
[TBL] [Abstract][Full Text] [Related]
10. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease.
Dupont-Lucas C; Sternszus R; Ezri J; Leibovitch S; Gervais F; Amre D; Deslandres C
J Crohns Colitis; 2016 Jul; 10(7):795-804. PubMed ID: 26822611
[TBL] [Abstract][Full Text] [Related]
11. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients.
Clarkston K; Tsai YT; Jackson K; Rosen MJ; Denson LA; Minar P
J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):68-74. PubMed ID: 31232885
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the infliximab therapy of severe form of pediatric Crohn's disease in Poland: Retrospective, multicenter studies.
Iwańczak BM; Ryżko J; Jankowski P; Sładek M; Wasilewska A; Szczepanik M; Sienkiewicz E; Szaflarska-Popławska A; Więcek S; Czaja-Bulsa G; Korczowski B; Maślana J; Iwańczak F; Kacperska M
Adv Clin Exp Med; 2017; 26(1):51-56. PubMed ID: 28397432
[TBL] [Abstract][Full Text] [Related]
14. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
[TBL] [Abstract][Full Text] [Related]
15. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
16. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
17. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
18. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
20. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
